181
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin

, , , , , , , , , & show all
Pages 2260-2262 | Received 21 Mar 2022, Accepted 30 Apr 2022, Published online: 20 May 2022
 

Disclosure statement

F.S. reports research funding from Roche Sequencing Solutions. All other authors do not report any conflicts of interest.

Additional information

Funding

This work was supported by Comprehensive Cancer Center Freiburg, by the Else Kröner-Fresenius-Stiftung (2018_A38, to F.S.), the Deutsche Forschungsgemeinschaft (SCHE 1870/3-1, to F.S.), the Fördergesellschaft Forschung Tumorbiologie (to F.S.), the Deutsche Gesellschaft für Innere Medizin (to F.S.), and the Biothera-Stiftung (to F.S.).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.